The Lancet Oncology
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Non-randomized trial in 55 peopleNavitoclax
7 papers1 new in 30 days